Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
Contact Us
繁
簡
EN
ABOUT ONENESS
Company Info
Company Organization
History
Core Value & Business Philosophy
Team
Global Partnership
Nanchou Plant
CEO Conversation
Animal Center
SCIENCE
PIPELINE
R & D
ON101
FB825
FB704A
SNS812
SNS851
Research Publication/ Abstract
FESPIXON®
FESPIXON® Cream
About Diabetic Foot Ulcers
Expanded Access Program
Medical Subsidies for low-Income DFU Patients
Care for Diabetic Foot
The Ph3 Data and the Mechanism of Action of FESPIXON®(ON101)
FESPIXON® received International Innovation Awards from Enterprise Asia
Bonvadis®
Hospital Location
Health Education
Diabetic Foot Care
ESG
ESG Overview
Message from the Chairman
Sustainable Management Structure
Stakeholders Engagement and Material Topics
2025 Sustainability Goals
Response to SDGs
ESG Awards and Highlights
Corporate Governance
Legal Compliance
Product Safety
Supply Chain Management
Environmental Protection
Environmental Management Systems
Climate Actions
Water Resources
Biodiversity
Chemical Substances and Waste Management
Social Inclusion
Diverse and Equal Workplace
Labor Rights
Talent Attraction, Retention, and Development
Healthy and Safe Working Environment
Access to Medicine
Social Engagement
ESG InfoHub
Latest ESG Report
Past ESG Reports
ESG Verification
Video Station
INVESTORS
Governance
Board of Directors
Functional Committee
Corporate Governance Officer Appointment
Internal Audit
Ethical Corporate Management
Risk Management
Cyber Security Management
Intellectual Property Management
Major Internal Policies
Shareholder Service
Annual Report
Shareholding Structure
Shareholder’s Meeting
Stock Quotes
Stock Dividend
Events & Presentations
Contact Audit Committee
Financial
Financial Report
Monthly Revenue
Investor FAQs
Investor Relations Contacts
NEWS
2025
2024
2023
2022
2021
2020
2019
2018
2017
CAREER
Choose Oneness Biotech
Learning Development
Compensation & Benefits
Join Us
The Company’s 2025Q2 consolidated financial statements have been approved by the Board of Directors
2025
2024
2023
2022
2021
2020
2019
2018
2017
Home
/
Latest News
/
2021
2021
Date
Title
2021-10-09
News-How effective is a new macrophage-regulating drug for wound healing in patients with diabetic foot ulcers?
>
2021-10-08
The Board of Directors of Oneness has approved a donation to Teh-Tzer Study Group for Human Medical Research Foundation.
>
2021-10-08
Oneness Biotech has been invited to present at the “10th Taiwan CEO Week on Air” online investor’s conference co-organized by TWSE and QIC.
>
2021-10-07
News-New Topical Drug Helps Foot Ulcers Heal in Clinical Trial
>
2021-09-15
Oneness announces the information about the investor’s conference of 2021 Q3.
>
2021-09-14
A Hong Kong patent titled “USE OF PATCHOULI EXTRACT IN THE PREPARATION OF COMPOSITIONS WITH AN ANTI-MICROORGANISM EFFECT” has been granted.
>
2021-09-10
Novel Diabetic Foot Ulcer Cream Shows Promise in Phase 3 Trial
>
2021-09-08
Novel macrophage-regulating cream demonstrated superior therapeutic efficacy for the treatment of diabetic foot ulcers compared to standard absorbent dressing
>
2021-09-07
RE: Novel Macrophage-Regulating Drug-Effect on Wound Healing in Patients With DFUs
>
2021-09-07
A novel macrophage-regulating new drug has shown promise in treating diabetic foot ulcers according to the latest issue of article published by the JAMA Network Open
>
2021-09-04
The data of the Phase 3 international multicenter clinical trial and the mechanism of action of Fespixon (ON101) have been published by JAMA Network Open
>
2021-09-04
Oneness decided not to proceed with FB704A phase 2 IND application in patients with severe COVID-19 based on strategic consideration
>
2021-09-03
Topical Cream Effective Against Diabetic Foot Ulcers — Investigational compound regulates macrophages, is “active-healing alternative,” researchers
>
2021-09-02
Oneness Biotech Co., LTD receives a Japanese patent on OB318, a new drug in development for liver cancer.
>
2021-08-10
Oneness Biotech Co., LTD receives a Chinese patent on OB318, a new drug in development for liver cancer.
>
« Previous
1
2
3
4
Next »
